VCYT: Double Bottom detected on 19 Oct 2026

VCYT is forming a double bottom pattern with structure score of 12.19 and volume support at 10.91, suggesting moderate consolidation quality. The stock trades at $43.12, bouncing between support at $41.22 and resistance at $49.00. Current volume at 2.06M shares shows 44% relative strength above the 20-day average of 1.43M, indicating institutional accumulation. The breakout score of 10.83 and overall score of 58.93 reflect a setup with reasonable technical foundation but not extreme conviction. RSI at 46.94 shows neutral momentum—neither oversold nor overbought—positioning the stock for directional expansion.

Veracyte delivered Q2 2026 record revenue of $150.3 million, up 15% year-over-year, with testing revenue of $145.7 million up 19% year-over-year. The company launched two new products in Q2: Prosigna LDT for breast cancer and TrueMRD for muscle invasive bladder cancer. Decipher Prostate grew 20% year-over-year with record orders per physician, while Afirma gained market share with 10% volume growth and 18% revenue growth. Management raised full-year 2026 revenue guidance to $590-$596 million, representing 14-15% growth, with testing revenue guidance of $576-$582 million. Most recently, Veracyte secured Medicare reimbursement for the Prosigna breast risk of recurrence test on October 16, 2026. This momentum supports the double bottom recovery pattern forming now.

A successful breakout above the $49.00 resistance would validate the double bottom structure and project a measured move target of $45.12 based on conservative estimate. Volume confirmation is critical—the pattern setup shows 44% above-average volume, but sustained breakout would require volume exceeding 1.9M shares on an upside close. The win probability score of 62.32% indicates better-than-coin-flip odds for pattern success. Invalidation occurs at support of $41.22; a close below this level would negate the double bottom setup and signal weakness. Historical double bottom patterns in this valuation range typically target 5-8% moves from breakout, consistent with the $45.12 target from the current $43.12 price.

Veracyte reports Q3 2026 earnings on November 4, 2026, creating near-term earnings volatility risk within 16 days. The stock is down 24.69% over three months and trades 29% below the 52-week high, suggesting prior institutional distribution. MACD histogram at -0.1042 shows weakening momentum despite price near double bottom. Volatility at 66.41% (20-day) is elevated for a healthcare diagnostics stock, increasing noise around the pattern. Beta of 0.69 provides defensive characteristics but limits upside participation if breakout succeeds. The broader market regime is bearish (score -0.26), conflicting with sector bullishness (score 0.94)—this disconnect may create unexpected volatility. Volume ratio of 1.44 is moderate; breakout authority weakens if volume fails to spike on upside breach.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.